Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

New combination therapy will be available on the NHS, offering new hope to people with advanced Hodgkin lymphoma ...

NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda.

Patients on Adcetris and chemo had better progression-free and overall survival after six years of follow-up compared to those on chemo only.

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended brentuximab ...

A new treatment for Hodgkin lymphoma has been recommended for routine use on the NHS. Around 800 people with the advanced ...

A new treatment for Hodgkin lymphoma has been recommended for routine use on the NHS. Around 800 people with the advanced ...

It is estimated that about 800 people with Hodgkin lymphoma could benefit from the decision by the National Institute for Health and Care Excellence.

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or following ...

Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated ...

Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.